Technical Analysis for CGEN - Compugen Ltd.

Grade Last Price % Change Price Change
grade B 3.77 1.89% 0.07
CGEN closed up 1.89 percent on Wednesday, March 20, 2019, on 71 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CGEN trend table...

Date Alert Name Type % Chg
Mar 20 Stochastic Sell Signal Bearish 0.00%
Mar 20 Overbought Stochastic Strength 0.00%
Mar 19 Inside Day Range Contraction 1.89%
Mar 19 Overbought Stochastic Strength 1.89%
Mar 18 Golden Cross Bullish -0.79%
Mar 18 Overbought Stochastic Strength -0.79%
Mar 15 Inside Day Range Contraction 1.34%
Mar 15 Overbought Stochastic Strength 1.34%
Mar 14 Bearish Engulfing Bearish 4.43%
Mar 14 20 DMA Support Bullish 4.43%

Older signals for CGEN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.
Medicine Biopharmaceutical Cancer Medical Specialties Life Sciences Immunology Treatment Of Cancer Antibodies Cancers Autoimmune Diseases Rheumatoid Arthritis Multiple Sclerosis Antibody Multiple Myeloma Monoclonal Antibody Autoimmunity Autoimmune Disorders Compugen Treatment Of Multiple Sclerosis Antibody Therapy
Is CGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.0
52 Week Low 2.0
Average Volume 156,301
200-Day Moving Average 3.3792
50-Day Moving Average 3.4428
20-Day Moving Average 3.567
10-Day Moving Average 3.625
Average True Range 0.1923
ADX 15.37
+DI 20.6688
-DI 20.5164
Chandelier Exit (Long, 3 ATRs ) 3.2631
Chandelier Exit (Short, 3 ATRs ) 3.5269
Upper Bollinger Band 3.9023
Lower Bollinger Band 3.2317
Percent B (%b) 0.8
BandWidth 18.800112
MACD Line 0.084
MACD Signal Line 0.066
MACD Histogram 0.018
Fundamentals Value
Market Cap 192.77 Million
Num Shares 51.1 Million
EPS -0.67
Price-to-Earnings (P/E) Ratio -5.63
Price-to-Sales 1330.24
Price-to-Book 3.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.97
Resistance 3 (R3) 3.96 3.88 3.93
Resistance 2 (R2) 3.88 3.83 3.89 3.92
Resistance 1 (R1) 3.83 3.80 3.86 3.84 3.91
Pivot Point 3.75 3.75 3.77 3.76 3.75
Support 1 (S1) 3.70 3.70 3.73 3.71 3.63
Support 2 (S2) 3.62 3.67 3.63 3.62
Support 3 (S3) 3.57 3.62 3.61
Support 4 (S4) 3.58